Risen Pharma, an internationally competitive clinical-stage innovative drug R&D group, has announced that its joint venture's application for the Class 1 new drug RP903 tablets has successfully received implicit approval for two clinical trials, with acceptance numbers CXHL2400566 and CXHL2400565. The primary target of this new drug, RP903 tablets, is to treat Proteus Syndrome (PROS), a rare but far-reaching disease associated with PIK3CA gene mutations. Dr. Lv Jiasheng, the founder and chairman of the group (a doctoral supervisor at Fudan University's School of Life Sciences and a researcher at the Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences), stated: "This achievement of Risen Pharma not only highlights its professional strength in the field of innovative drug development but also suggests potential breakthroughs in the treatment of rare pediatric diseases in the future."